Clinical Trial Update: A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate ALTA3263 in adults with KRAS-mutant advanced solid tumors, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ALTA3263

Snippet

Sponsor: Alterome Therapeutics, Inc. | Conditions: Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: RECRUITING